Description: Summary of lessons learned from Health Insurer Chief Actuaries' prior economic recession experience and suggestions for those leading Health insurers through future recessions

Description: MACRA not only impact providers, it will impact the entire healthcare market. MACRA published studies and commentary to date have primarily focused on providers, with the majority of the information addressing the impacts to clinicians. However, our investigation indicates MACRA has far reaching impacts to payers as well as providers. MACRA is impacting each geographic market and line of business in a unique way, and health payers will have multiple strategic decisions to consider given the changing market dynamics.

Description: This article describes various insurance products now offered to SOA members as an affinity group.

Description: This article is an update on the No Surprises Act, which is a U.S. Act aimed to reduce the risk that a person unexpectedly receives out of network charges for their health care visits.

Description: Comparison of domestic and international PFML programs

Description: This is a book review of 'What Healthy People Know by Dr. Bob Gleeson, a book focusing on the seven things that healthy people do to say healthy and live long. The reviewer relates these activities to the actuarial career.

Description: This is an introduction to the SOA call for essays around risk strategies pertaining to the diverse risks found in retirement. We are pleased that these essays can be included in this issue of Pension Section News, along with a short interview with each author.

Description: This paper explores how health care complexity challenges us to expand our repertoire of actuarial methods—and even recast our trend driver paradigm—in order to do our jobs better and maintain our credibility.

Description: Letter from the Editor Greetings to All Health Actuaries! by Jeffrey D. Miller from Health Section News, April 2001, Issue No. 40.

Description: The coming wave of biosimilars could dramatically affect prescription drug costs and benefit strategies over the next several years. The launch of many Humira biosimilars in 2023 is the Big Event that will largely determine the impact of the biosimilar wave. Payers have many decisions to make about coverage and formulary tiers. What factors will drive payer decision-making?